Evidence map›Paper›PMID 41003647›Full record

ArticleCancer research communications2025

Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification.

Adel T Aref, Jason Grealey, Mohashin Pathan, Zainab Noor, Asim Anees, A K M Azad, Daniela Lee Smith, Erin M Humphries, Daniel Bucio-Noble, Jennifer M S Koh and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. From metabolic dysregulation to malignancy: the presence ofJournal of gastrointestinal oncology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Adel T Aref *ProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID 0000-0003-3028-131X
Jason Grealey *ProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID 0000-0001-5236-5958
Mohashin PathanProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID 0000-0001-7071-0022
Zainab NoorProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID 0000-0002-9314-5705
Asim AneesProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID 0000-0003-2220-0874
A K M AzadProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID 0000-0002-5251-2214
Daniela Lee SmithProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID 0009-0005-2227-0858
Erin M HumphriesProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID 0000-0001-7186-0620
Daniel Bucio-NobleProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID 0000-0001-7603-8732
Jennifer M S KohProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID 0000-0003-2140-3151
Erin K SykesProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID 0000-0002-1582-5238
Steven G WilliamsProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID 0000-0003-4647-436X
Ruth J LyonsCancer Division, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, University of New South Wales, Darlinghurst, Australia.ORCID 0009-0000-3665-0302
Natasha LucasProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID 0000-0002-7656-6866
Dylan XavierProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID 0000-0003-2601-9343
Sumit SahniUniversity of Sydney, Sydney, Australia.ORCID 0000-0002-2900-8845
Anubhav MittalUniversity of Sydney, Sydney, Australia.ORCID 0000-0003-3960-2968
Jaswinder S SamraUniversity of Sydney, Sydney, Australia.ORCID 0000-0001-6664-7147
John V PearsonQIMR Berghofer Medical Research Institute, Brisbane, Australia.ORCID 0000-0003-0904-4598
Nicola WaddellQIMR Berghofer Medical Research Institute, Brisbane, Australia.ORCID 0000-0002-3950-2476
Olga KondrashovaQIMR Berghofer Medical Research Institute, Brisbane, Australia.ORCID 0000-0003-0022-5149
Angela ChouCancer Division, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, University of New South Wales, Darlinghurst, Australia.ORCID 0000-0001-9212-6927
Loretta SiosonNSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, Australia.ORCID 0009-0001-8533-5736
Amy SheenUniversity of Sydney, Sydney, Australia.ORCID 0000-0001-8974-6092
Australian Pancreatic Cancer Genome Initiative (APGI)
Peter G HainsProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID 0000-0002-7276-1760
Phillip J RobinsonProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID 0000-0002-7878-0313
Qing Zhong *ProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID 0000-0002-5340-301X
Roger R Reddel *ProCan, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia.ORCID 0000-0002-6302-6107
Anthony J Gill *Cancer Division, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, University of New South Wales, Darlinghurst, Australia.ORCID 0000-0002-9447-1967

Funding

Australian Cancer Research Foundation (ACRF) 2017/TPG001Australian Cancer Research Foundation (ACRF) REG171150Ian Potter Foundation (IPF) MRFF-PDNSW Ministry of Health CMP-01PanKind, The Australian Pancreatic Cancer Foundation (PanKind)
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy that lacks reliable biomarkers to guide treatment decisions. Effective prognostic tools are needed to improve its clinical management. We conducted a comprehensive proteomic analysis on 115 PDA patient samples with matched adjacent normal tissue. A 20-protein diagnostic panel was identified (LGALS1, ANXA2, LGALS3BP, CTSD, S100P, COL12A1, SFN, THBS2, CTHRC1, THBS1, SERPINB5, LAMC2, POSTN, CEACAM6, CTSE, PLEC, PKM, S100A11, TAGLN2, ALDOA). Consensus clustering analysis identified four prognostic proteomic subtypes. Subtypes with poorer prognoses exhibited upregulation of neutrophil degranulation, extracellular matrix remodeling, focal adhesion, Mesenchymal Epithelial Transition, collagen formation, and PI3K-Akt-mTOR-related pathways, indicating a predominance of basal-like and activated stromal features. In tumors with homologous recombination deficiency or Catalogue of Somatic Mutations in Cancer Signature-3, several immune-related proteins were enriched. An 18-protein (PURB, SDCBP2, CD2BP2, GALM, SERPINA3, OAS3, FAN1, ZPR1, KRT2, NUDT2, SMNDC1, SERPINA4, CUTA, WDR36, POSTN, CLEC11A, PEX14, and PI4KA) risk score was developed and validated using multicox regression analyses with LASSO regularization. The risk score demonstrated independent prognostic significance for overall survival and recurrence, and was validated in an independent proteomic dataset generated using a different proteomic technology. This study thus introduces four novel prognostic PDA subtypes, and an 18-protein risk score validated in an independent dataset, which shows promise for improving survival prediction and could serve as a valuable tool for personalized treatment guidance. SIGNIFICANCE: The findings from this study have significant implications for the future of pancreatic cancer management. By identifying a 20-protein panel with diagnostic and screening potential, this research provides a foundation for developing early detection tools for PDA, an aggressive cancer with limited treatment options. The classification of PDA into four proteomic subtypes with distinct prognostic outcomes paves the way for subtype-specific therapeutic approaches, allowing clinicians to better stratify patients based on their risk profiles. Additionally, the validated 18-protein risk score, which enhances survival prediction and operates independently of existing clinical variables, represents a promising tool for personalized prognostic assessments. Incorporating these proteomic-based biomarkers into clinical practice could improve diagnostic accuracy, guide individualized treatment decisions, and ultimately enhance patient outcomes in PDA. This study underscores the potential of proteomic profiling to improve cancer treatment by providing targeted, actionable insights into tumor biology.

Indexed as

Biomarkers, TumorCarcinoma, Pancreatic DuctalPancreatic NeoplasmsProteomicsAgedFemaleHumansMaleMiddle AgedPrognosisBiomarkers, Tumor

Identifiers

PMID41003647
PMCPMC12548992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.